

1 **Modeling of drug release, erosion and diffusion fronts movement in high**
2 **viscosity HPMC matrices containing a cellulolytic enzyme**

3
4 Ilaria Filippin¹, Saliha Moutaharrik^{1*}, Michela Abrami², Lucia Grassi², Andrea
5 Gazzaniga¹, Alessandra Maroni¹, Mario Grassi², Anastasia Foppoli¹

6
7
8
9
10 ¹Università degli Studi di Milano

11 Dipartimento di Scienze Farmaceutiche

12 Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli"

13 via G. Colombo 71

14 20133 Milano, Italy

15
16
17 ²Università degli Studi di Trieste,

18 Dipartimento di Ingegneria e Architettura

19 Building B, via Valerio 6

20 34127 Trieste, Italy

21
22
23 Corresponding Author:

24 Saliha Moutaharrik

25 tel +39 02 50324655

26 email: saliha.moutaharrik@unimi.it

27
28
29
30
31

32

33 **ABSTRACT**

34

35 A formerly developed mathematical model describing drug release from
36 hydrophilic matrices (HMs) took into account resistance to drug release given by
37 its dissolution and by the presence of a growing gel layer. Such a model was
38 applied to previously reported release data obtained from HMs made of
39 hydroxypropyl methylcellulose (HPMC), where acetaminophen was used as model
40 drug and a cellulolytic product was added as “active” excipient to attain zero-order
41 release kinetics.

42 The Levich theory applied to acetaminophen IDR data highlighted the suitability
43 of such a drug for modeling purposes, given its good surface wettability. First
44 assessment of the model ability to describe drug release from the abovementioned
45 systems was carried out on partially coated matrices, representing a simplified
46 physical frame, but results were then confirmed on uncoated systems.
47 Experimental and model release data showed good agreement; therefore, the
48 release-describing equation was combined with that of the global mass balance to
49 obtain two new equations related to erosion and diffusion fronts time evolution.
50 Changes over time in the dissolution and gel contributions to total resistance,
51 calculated using model output parameters, highlighted that the enzyme, through
52 its hydrolytic activity on HPMC, was responsible for a time-dependent reduction
53 of the resistance component related to gel layer.

54

55 **KEYWORDS**

56 Mathematical Modeling

57 Hydroxypropylmethylcellulose (HPMC)

58 Hydrophilic matrix

59 Cellulase

60 Erosion and swelling fronts

61 Release mechanism

1. INTRODUCTION

Prolonged-release systems are designed to maintain the therapeutic effect of a selected drug for an extended period of time (Wang et al., 2020). This feature generally avoids the peak-valley plasmatic concentration profile typical of multiple administrations of conventional release dosage forms, thus possibly lowering the probability of side effects occurrence and reducing the number of administrations, ultimately improving patients' compliance (Jantzen and Robinson, 2002).

Hydrophilic matrices (HMs) are well-established prolonged release dosage forms (Ghori and Conway, 2015). They are robust systems which show poor manufacturing complexity, as they are generally obtained from consolidated techniques such as tableting, casting or extrusion of a drug – swellable polymer mixture (Loreti et al., 2013; Wen et al., 2010; Zhang and McGinity, 1999). The hydrophilic derivatives of cellulose, particularly hydroxypropyl methylcellulose (HMPC), are the most frequently utilized class of swellable polymers for the preparation of HMs.

As all prolonged release systems, HMs are in principle designed to provide zero-order kinetics, a prerequisite to achieve constant plasma drug levels throughout the whole release duration (Laracuenta et al., 2020). Nevertheless, upon contact with the aqueous media, matrices are subjected to various and concomitant phenomena which result in a non-linear release profile (Colombo, 1993; Timmins et al., 2016; Tiwari et al., 2011; Vázquez et al., 1992). After a burst effect due to drug dissolution at the matrices surface, a pseudo-linear phase can be observed. In this segment, the polymer undergoes a glass-rubbery transition with the formation of a gel layer (Jamzad et al., 2005). The drug, which dissolves at the swelling front (*i.e.* the surface between the matrix still in the glassy state and the gel layer) can diffuse through the gel to reach the outer surface of the matrix (*i.e.* erosion front) and finally be liberated into the dissolution medium (Colombo et al., 2000, 1987; Tiwari and Rajabi-Siahboomi, 2008). A third front delimiting a gel layer area with undissolved drug, namely diffusion front, can be present. Its position

92 depends on drug solubility and drug load (Colombo et al., 1999; Ferrero et al.,
93 2010). The swelling front upon solvent penetration moves inwards, while the
94 erosion front tends to move outwards - because of polymer swelling - until matrix
95 volume increasing is counterbalanced by the polymer erosion-dissolution
96 phenomenon (Deering et al., 2008; Mašková et al., 2020; Salsa et al., 2008). This
97 combined movement is responsible for an increase of drug diffusional path and a
98 decrease of the area available for drug dissolution over time, leading to a
99 progressive drop of drug release rate (Colombo et al., 1995; Harland et al., 1988).
100 Through the years, many researchers have explored various strategies to obtain
101 zero-order kinetics from HMs, mainly by modifying their basic design in terms of
102 geometry and/or composition. (Cerea et al., 2020a, 2020b, 2018; Conte et al.,
103 1993; Ford et al., 1987; Gander et al., 1988; Gazzaniga et al., 1993; Kim, 1995;
104 Moodley et al., 2011; Ranga Rao et al., 1988; Sangalli et al., 1994). Recently, the
105 use of cellulase, a cellulolytic enzymatic complex, as “active” excipient was
106 proposed in HPMC-based oral delivery systems, namely in a time-dependent
107 reservoir system and in prolonged release HMs (Foppoli et al., 2020; Gazzaniga et
108 al., 2022, Palugan et al., 2021). Cellulase is indeed able to exert hydrolytic activity
109 not only on its natural substrate, cellulose, but also on hydrophilic cellulose
110 derivatives, such as HPMC (Caceres et al., 2020).

111 As far as matrices are concerned, the observed general increase of release rate
112 was effective in counteracting its late decrease and, when considering relatively
113 high concentration of the enzymatic complex, also in masking the initial burst
114 effect. In depth studies of the mechanisms involved into the release profiles shift
115 towards linearity highlighted that the main phenomena involved in drug release
116 were modified by the hydrolytic action of the enzyme on the polymer, although to
117 a different extent. Specifically, polymer swelling, intended as glassy-rubbery
118 transition rate, was poorly affected by cellulase activity, while erosion and
119 dissolution of the matrices were clearly enhanced because of the formation of
120 shorter polymeric chains (Palugan et al., 2021). In fact, the enzyme-related
121 glycosidic bonds cleavage can be considered as a further phenomenon operating

122 during drug release, which was also responsible for a faster drug diffusion through
123 an increasingly permeable gel layer. In other words, cellulase could be considered
124 as an “active” excipient which, through its hydrolytic activity, was found able to
125 progressively lower the gel layer resistance to molecular diffusion.

126 Mathematical modelling of drug release from HPMC matrices has been pursued
127 by many researchers over the years (Peppas and Narasimhan, 2014). In a model
128 previously reported by some of us, the general equation for drug dissolution was
129 adapted to describe drug release from HMs by adding the resistance to drug
130 diffusion, which depends by both contribution of the dissolution phenomenon and
131 the gel layer (Grassi et al., 2004).

132 In the present work, the suitability of this mathematical model to describe drug
133 release from matrices containing a cellulolytic product was evaluated, and derived
134 new equations able to define the erosion and diffusion fronts positions over time
135 were sought. For a first assessment of the model suitability, previously published
136 data obtained from tableted HMs partially coated on all the surface except for one
137 base were used (Palugan et al., 2021). This feature, allowing the surface of the
138 active substance in contact with the solvent to remain constant, made the physical
139 frame to be modeled less complex. The ability of the equations to predict both
140 release and fronts positions was estimated not only on this simplified
141 configuration, but also on uncoated matrices exposing their entire surface to the
142 dissolution medium.

143

144

145

146 **1.1. Mathematical Modeling**

147

148 *1.1.1. Release and fronts position*

149 Mathematical modeling of drug release from HPMC matrices has attracted the
150 attention of many researchers over the years leading to the publication of various
151 and powerful descriptive models (Adrover et al., 2018; Caccavo et al., 2017;

152 Chirico et al., 2007; Guiastrennec et al., 2017; Saeidipour et al., 2017; Siepmann
 153 and Peppas, 2012, 2001). With the aim to develop a simple and reliable model to
 154 describe the behavior of HPMC matrices formulated with a cellulolytic enzymatic
 155 complex, in this work an already existing mathematical model, which proved to
 156 be reliable in describing the release of diprophylline and theophylline from HPMC
 157 matrices, was implemented (Grassi et al., 2004). This model was obtained
 158 following the main idea of generalizing the classical Noyes and Whitney (Noyes
 159 and Whitney, 1897) equation describing the dissolution of drug particles
 160 (Siepmann and Siepmann, 2013):

161

$$162 \quad \frac{dC}{dt} = \frac{DA}{Vh} (C_s - C) \quad (1)$$

163

164 where t is time, C and C_s are drug concentration and solubility in the dissolution
 165 medium, respectively, D is the diffusion coefficient in the dissolution medium, A is
 166 the surface area at the solid/liquid interface, V is the dissolution medium volume,
 167 h is the stagnant layer thickness surrounding the solid and the ratio D/h represents
 168 the intrinsic dissolution rate constant k_d . Obviously, eq.(1) holds in the hypothesis
 169 of negligible mass transport resistance at the solid-liquid interface, this being
 170 typical of easily wettable solids (Abrami et al., 2020). Bearing in mind that the
 171 global diffusional resistance of a multi-layered membrane is the sum of the
 172 resistance of each layer (Flynn et al., 1974), eq.(1) can be adapted to describe drug
 173 release from a hydrophilic matrix by properly incorporating the diffusion step of
 174 the drug through the gel layer:

175

$$176 \quad \frac{dC}{dt} = \frac{\varphi_d A}{V} \frac{(C_s - C)}{\left(\frac{1}{k_d} + R\right)} \quad (2)$$

177

178 where j_d is the drug volume fraction and R the gel layer resistance ($1/R$ can also
 179 be defined as gel permeability, P). The global resistance to drug release is given
 180 by the sum of the dissolution phenomenon resistance ($1/k_d$) and the resistance to

181 drug diffusion through the gel layer (R). As A represents the area at the interface
 182 between the polymer in the glassy and rubbery state (*i.e.* at the swelling front), $j_d A$
 183 indicates the drug-liquid surface area at the swelling front (Lombardi et al., 1998).
 184 Notably, eq.(2) also holds for drug release in non-sink conditions due to the
 185 presence of the $(C_s - C)$ term and it has the advantage of degenerating into eq.(1)
 186 for tablets made of drug only ($j_d = 1$; $R = 0$). As drug diffusion rate through a gel
 187 layer can reasonably be correlated to the layer thickness, the analysis of
 188 experimental data regarding the temporary evolution of the gel thickness
 189 (Cappello et al., 1994; Colombo et al., 1999; Sai Cheong Wan et al., 1995) leads to
 190 conclude that a reasonable, although empirical, R time variation can be expressed
 191 by eq.(3):

192

$$193 \quad R = B(1 - e^{-bt}) \quad (3)$$

194

195 where B represents the asymptotic value of R and b rules the kinetics of R variation.

196 Both B and b are model parameters to be determined by data fitting.

197 Due to its empirical nature, equation (3) can properly account for other phenomena
 198 concurring to the diffusional resistance such as the influence of variation of A over
 199 time and the drug transport in different directions. When dealing with cylindrical
 200 tablets that are coated on all the surface except one base with an impermeable
 201 film, A is substantially constant and drug transport is, essentially, one-dimensional
 202 (the direction normal to the tablet plane surface). On the contrary, in the case of
 203 uncoated tablets, A is time dependent and drug diffusion becomes, in principle,
 204 three-dimensional.

205 Embodying eq.(3) into eq.(2) and solving for C assuming that drug concentration
 206 (C) in the release environment is zero at the beginning of the experiment ($t = 0$),
 207 leads to model analytical expression (Demidovic, 1975) of eq.(4):

208

$$209 \quad C = C_s \left(1 - \left(e^{bt} \left(1 + Bk_d(1 - e^{-bt}) \right) \right)^{-\frac{A\varphi_d}{bV \left(B + \frac{1}{k_d} \right)}} \right) \quad (4)$$

210

211 which, in terms of amount of drug released ($M = CV$) becomes eq.(5):

212

$$213 \quad M = VC_s \left(1 - \left(e^{bt} \left(1 + Bk_d(1 - e^{-bt}) \right) \right)^{\frac{A\varphi_d}{bV(B + \frac{1}{k_d})}} \right) \quad (5)$$

214

215 It should be noted that eq.(4) or (5) hold as far as either drug solid particles and a
 216 glassy portion of the matrix exist, *i.e.* until the swelling front reaches the bottom of
 217 the coated tablet or the center of the uncoated one.

218 Interestingly, coupling of eq.(4) with the global drug mass balance enables the
 219 theoretical evaluation of the time position of both the dissolution (X_d) and the
 220 erosion (X_e) fronts. Indeed, the global mass balance ensures that the initial drug
 221 amount contained in the tablet (M_0) must be equal, at any time, to the amount of
 222 drug released in the medium ($C \cdot V$) plus the amount still present in the tablet
 223 ($A \cdot X_d \cdot C_0 + M_g$), according to eq.(6):

224

$$225 \quad M_0 = CV + AX_d C_0 + M_g \quad (6)$$


226

227 where C_0 is the initial drug concentration in the tablet and M_g is the drug amount
 228 contained inside the gel layer. Assuming a linear decrease of drug concentration
 229 within the gel layer, *i.e.* from the diffusion to the erosion front (Figure 1), M_g can
 230 be estimated according to eq.(7):

231

$$232 \quad M_g = A \int_0^{X_e - X_d} \left(\frac{C - C_s}{X_e - X_d} y + C_s \right) dy = A(X_e - X_d) \left(\frac{C + C_s}{2} \right) \quad (7)$$

233



234

235 Figure 1. Schematic of fronts position and drug concentration profile in a partially
 236 coated hydrophilic matrix. C_0 , C_s and C represent, respectively, the initial drug
 237 concentration in the tablet, the drug solubility and the drug concentration in the
 238 external fluid. X_e , X_d and X_s indicate, respectively, the erosion, the diffusion and the
 239 swelling fronts positions while X_{e0} , X_{d0} and X_{s0} are the respective positions at $t=0$.

240

241 Remembering that R represents the mass transfer resistance inside the gel layer,
 242 its mathematical definition reads:

243

$$244 \quad R = \frac{X_e - X_d}{D_m k_p} \quad (8)$$

245

246 *i.e.*, R is the ratio between the gel layer thickness ($X_e - X_d$) and the product of drug
 247 diffusivity in the gel (D_m) times the drug partition coefficient (k_p) between the gel
 248 and the external liquid phase. Should the diffusing drug molecules interact with
 249 the polymer chains and/or should the gel structure not be homogeneous, D_m can
 250 be considered as an effective diffusion coefficient, the values of which depends on
 251 the strength of drug interaction with polymeric chains and the gel structure
 252 heterogeneity (Grassi et al., 2006). Eq.(8) allows expressing the gel layer thickness
 253 ($X_e - X_d$) as the product $R \cdot D_m \cdot k_p$ that, in turn, can be embodied into eq.(6) in order
 254 to easily determine X_d :

255

$$X_d = \frac{M_0}{AC_0} - \frac{\left(\frac{V}{A} + \frac{RDmk_p}{2}\right) + RDmk_p \frac{C_s}{2}}{C_0} \quad (9)$$

257

258 Finally, in the light of eq.(8), it is possible getting the position of the erosion front

259 X_e :

260

$$X_e = \frac{M_0}{AC_0} - \frac{C \frac{V}{A} + RDmk_p \left(\frac{C+C_s}{2} - C_0\right)}{C_0} \quad (10)$$

262

263 It is important to underline that at the beginning of the experiment ($t = 0$), both R
 264 and C are equal to zero, so that the positions of the erosion and the diffusion front
 265 coincide, residing in the initial surface of the tablet in contact with the fluid. In
 266 addition, coherently, subtraction of eq.(9) from eq.(10) provides the gel layer
 267 thickness ($X_e - X_d$) that, according to eq.(8) is equal to $R \cdot D_m \cdot k_p$.

268 In conclusion, the proposed model is characterized by four fitting parameters. B
 269 and b connected to the evolution of the gel layer thickness (eq.(3)), k_d related to
 270 the intrinsic drug dissolution (eq.(2)) and D_m that is the average drug diffusion
 271 coefficient in the gel layer (eq.(8)). The simultaneous fitting of eq.(5) and eq.(10),
 272 respectively, to the experimental data referring to the amount of drug released and
 273 the position of the erosion front, allows the determination of B , b , k_d and D_m .

274

275 1.1.2. Intrinsic Dissolution Rate (IDR)

276 To better understand the physics of drug release from HPMC matrices containing
 277 different amounts of cellulase, it is useful to theoretically analyze the outcomes of
 278 intrinsic dissolution rate (IDR) test (Grassi et al., 2006). Fixed or rotating disk
 279 configurations are typically the most common apparatuses used to perform IDR
 280 tests. In the former configuration, which was selected for this work, the relative
 281 velocity between the stationary disk and the fluid under motion (given by the
 282 paddle rotating at different speed) affects the rate of drug dissolution, the kinetics
 283 of which is essentially regulated by the formation of a stagnant liquid layer adjacent
 284 to the solid surface.

285 The simultaneous solution of the momentum and the continuity equations referred
 286 to the dissolution medium and the solution of the mass balance equation referred
 287 to the drug, allowed Levich (Levich, 1962) to demonstrate that, in the rotating disk
 288 configuration, the average stagnant layer thickness δ , is given by:

289

$$290 \quad \delta = 1.61 \sqrt[3]{\frac{D^2}{\nu}} \sqrt{\frac{\nu}{\omega}} \quad (11)$$

291

292 where ν is the dissolution medium kinematic viscosity and D is the drug diffusion
 293 coefficient in the dissolution medium and ω is the angular velocity of the fluid-disk
 294 relative motion. A similar analysis led by Khoury and co-workers (Khoury et al.,
 295 1988) on the fixed disk configuration, revealed that eq.(11), basically, still holds but
 296 with a different multiplying constant, to be determined from experimental data.
 297 Consequently, the intrinsic dissolution constant k_d , *i.e.* the ratio between D and δ ,
 298 descending from the Levich approach (eq.(11)) still holds but with a different
 299 multiplying constant ($F_a \cdot 0.621$):

300

$$301 \quad k_d = \frac{D}{\delta} = F_a 0.621 D^{\frac{2}{3}} \nu^{-\frac{1}{6}} \sqrt{\omega} \quad (12)$$

302

303 In the IDR case, eq.(2) becomes (Abrami et al., 2020):

304

$$305 \quad \frac{dC}{dt} = \frac{S}{V} \frac{(C_s - C)}{\left(\frac{1}{k_d} + \frac{1}{k_m}\right)} \quad (13)$$

306

307 where S is the dissolution area, V is the dissolution medium volume and k_m is the
 308 interface mass transfer coefficient mainly depending on the dissolution surface
 309 wettability. In other words, $1/k_d$ and $1/k_m$ represent, respectively, mass transfer
 310 resistance due to the presence of the stagnant layer and due to solid surface
 311 wettability issues. Eq.(13) solution, in the light of eq.(12), leads to eq.(14):

312

$$C = C_s \left(1 - e^{\left(\frac{-S}{V} \frac{t}{\frac{1.61}{F_a} D^{-\frac{2}{3}} \frac{1}{v^6} \omega^{-\frac{1}{2}} + \frac{1}{k_m}} \right)} \right) \quad (14)$$

314

315 where F_a and k_m need to be determined by eq.(14) fitting to experimental IDR data
 316 performed at different paddle rotation speed.

317

318 **2. EXPERIMENTAL**

319

320 **2.1. Materials**

321 Acetaminophen (AMP, C.F.M., Italy), M_w 151,2 g/mol, water solubility 18 g/L at
 322 37 °C, true density 1.214 g/cm³. Hydroxypropyl methylcellulose 2208 USP
 323 (HPMC, Methocel® K4M, Mn = 86000, Dow Italia, Italy), true density 1.326 g/cm³.
 324 Sternzym® C13030 (SternEnzym GmbH and Co. KG, Germany -kindly donated by
 325 IMCD Italia, Italy) 2500 U/g enzymatic activity, expressed as hemicellulase
 326 according to DNS method at pH 6.0 as reported in the product technical data
 327 sheet. Cellulose acetate propionate (CAP 482–20, Eastman-Kodak, Tennessee,
 328 US).

329

330 **2.2. Methods**

331 *2.2.1. Intrinsic dissolution test*

332 AMP powder samples were compacted by means of a hydraulic press in a round
 333 Ø=11 mm matrix, under approximately 3 tons force for 3 min. The obtained
 334 compacts were maintained inside the matrix and tested in a USP43 Apparatus 2
 335 (Distek Dissolution System 2100B) under the following conditions: 500 mL of
 336 distilled water at 37°, paddle height set at 2.5 cm from the compacts surface,
 337 rotation speed 50, 75, 100 or 125 rpm. The concentration of drug in the dissolution
 338 medium at each time point was determined spectrophotometrically at 243 nm.
 339 The test was performed in 3 replicates.

340 *2.2.2. True density determination*

341 Literature-reported true density values were used for AMP (1.214 g/cm³) and
 342 HPMC (1.326 g/cm³) (ECHA, 2012; Rogers T L, 2009). For the cellulolytic product,
 343 the value was experimentally determined. Sternzym[®] C13030 powder was
 344 compacted in a round Ø=11 mm matrix with a hydraulic press applying 15 tons
 345 force for 6 min under vacuum (n=3). Then, weight and height of each compact
 346 were measured to calculate true density (1.391 g/cm³).

347 2.2.3. Preparation and testing of matrices

348 Mass loss, release, erosion and swelling fronts positions data used for
 349 mathematical modeling are those published in Palugan et al., 2021. Two types of
 350 systems were prepared from a mixture of AMP and HPMC in a 1:1 w/w ratio,
 351 either as such or containing different amounts of Sternzym[®] C13030, following the
 352 compositions reported in Table 1. Cylindrical flat faced units (diameter 25 mm,
 353 height 3.15 mm, nominal weight 1.5 g) were partially coated on the entire surface
 354 except for one base with an impermeable film manually applied by dipping into a
 355 15% w/v CAP solution in acetone. The partially coated matrices (CM systems),
 356 after being ballasted by gluing the coated base to a stainless-steel disk, were tested
 357 for release (spectrophotometric determination of AMP at $\lambda = 243$ nm), mass loss
 358 by gravimetric method, erosion and swelling fronts position measurements by
 359 means of a penetrometer. Uncoated convex-faced units (diameter 11 mm, height
 360 2.2 mm, nominal weight 0.24 g) underwent only release tests (UM systems).

361

362 Table 1 – Weight percentage composition of the partially coated (CM) and
 363 uncoated matrices (UM) under investigation. Percentage of Sternzym[®] C13030 is
 364 also reported as calculated on HPMC.

Code		AMP	HPMC	Sternzym [®] C13030	<i>Sternzym[®] C13030 with respect to HPMC</i>
25 mm partially coated	11 mm uncoated				
CM ₀	UM ₀	50.00	50.00	-	-
CM _{0.5}	UM _{0.5}	49.88	49.88	0.25	0.5

CM ₁	UM ₁	49.75	49.75	0.50	1
CM ₅	UM ₅	48.78	48.78	2.44	5
CM ₁₀	UM ₁₀	47.62	47.62	4.76	10

365

366


367 **3. RESULTS AND DISCUSSION**

368

369 **3.1.IDR**

370 Due to eq.(14) mathematical features, the determination of the unknown
 371 parameters F_a and k_m requires the simultaneous fitting of eq.(14) to each set of
 372 experimental data, obtained from IDR tests performed at different paddle rotation
 373 speed, *i.e.* 50, 75, 100 and 125 rpm (angular velocity $\omega = (50, 75, 100 \text{ and } 125$
 374 rpm)* $\pi/30$)

375



376

377 Figure 2. IDR of acetaminophen obtained in thermostated water ($T = 37^\circ\text{C}$) at
 378 different paddle rotation speed. Symbols indicate experimental data while lines
 379 represent best fitting according to eq.(14). Vertical bars indicate standard
 380 deviation

381

382 A rather good agreement was found between eq.(14) best fitting and the
383 experimental data corresponding to all the considered paddle velocities (Figure 2).
384 This qualitative statement is statistically supported by the F -test score ($F(1, 28,$
385 $0.95) < 293$). Data fitting, performed assuming $T = 37^\circ\text{C}$, $\nu = 6.96 \cdot 10^{-7} \text{ m}^2/\text{s}$
386 (water), $C_s = 18 \text{ kg}/\text{m}^3$, $S = 3.8 \cdot 10^{-4} \text{ m}^2$ and $V = 5 \cdot 10^{-4} \text{ m}^3$ and $D = 7.8 \cdot 10^{-10} \text{ m}^2/\text{s}$
387 (calculated on the basis of the Stokes-Einstein equation assuming acetaminophen
388 molar volume equal to $1.844 \cdot 10^{-4} \text{ m}^3/\text{mole}$ (Iqbal and Malik, 2005), this corresponding
389 to a radius of 0.418 nm), provides $F_a = (0.42 \pm 0.02)$ and $k_m \geq 1 \text{ m}/\text{s}$ as whatever
390 $k_m \geq 1$, fitting quality no longer improves. Notably, the high k_m value ensures that
391 acetaminophen dissolution is substantially not affected by surface resistance to
392 drug dissolution. Indeed, wherever the mass transfer resistance due to interface
393 ($R_m = k_m^{-1}$) is $\leq 1 \text{ s}/\text{m}$, the mass transfer resistance due to presence of the stagnant
394 layer ($R_d = k_d^{-1}$) is about five order of magnitude bigger (see Table 2), this meaning
395 that the effect of the stagnant layer on the mass transport is much more important
396 than that exerted by the surface resistance to dissolution. Thus, acetaminophen is
397 easily wettable by water.

398 Table 2. Model parameters related to eq.(14) fitting to experimental IDR data performed at different paddle rotation speed:
 399 interface mass transfer coefficient (k_m), intrinsic dissolution constant (k_d), interfacial (R_m) and hydrodynamic (R_d) mass transfer
 400 resistances and thickness (δ) of the stagnant layer adhering to the fixed solid surface. k_m and F_a derive from fitting of eq.(14) to
 401 experimental data, δ and k_d are calculated according to eq.(12).


Paddle rotation speed (rpm)	50	75	100	125
F_a	0.42 ± 0.02			
k_m (m/s)	≥ 1			
k_d (m/s)	$(5.38 \pm 0.25) \cdot 10^{-6}$	$(6.58 \pm 0.3) \cdot 10^{-6}$	$(7.60 \pm 0.36) \cdot 10^{-6}$	$(8.50 \pm 0.40) \cdot 10^{-6}$
R_m (s/m)	≤ 1			
R_d (s/m)	$(1.86 \pm 0.89) \cdot 10^5$	$(1.52 \pm 0.72) \cdot 10^5$	$(1.31 \pm 0.62) \cdot 10^5$	$(1.17 \pm 0.56) \cdot 10^5$
δ (μm)	145 ± 7	118 ± 6	102 ± 5	92 ± 4

402


403 **3.2. Partially coated matrices**

404 Figure 3 shows the simultaneous best fitting of the proposed mathematical model
405 (lines) to experimental data (symbols) referring to the amount of released
406 acetaminophen (Figure 3A – eq.(5)) and the position of the erosion front (Figure
407 3B – eq.(10)) relative to the enzyme-free system CM_0 . While the statistical reliability
408 of model best fitting is proved by the F -test score ($F(3, 19, 09.95) < 9660$), its
409 physical soundness is proved by the values of the fitting parameters. Indeed, k_d
410 $((4.8 \pm 0.2) \cdot 10^{-6} \text{ m/s})$ is slightly smaller than k_{d-IDR} (Table 2). This difference is
411 reasonable, considering that the HPMC network creates an almost static
412 hydrodynamic condition around the particles.

413



414



415


416 Figure 3. A) Model best fitting (solid line – eq.(5)) to experimental release data (M_d ,
 417 open circles) of the enzyme-free matrix CM_0 . B) Model best fitting (solid line –
 418 eq.(10)) to experimental data (open rhombi) referring to the position of the erosion
 419 front (X_e) with respect to its initial position (X_{e0}). The dashed line represents the
 420 calculated displacement (eq.(9)) of the diffusion front (X_d) from its initial position
 421 (X_{d0}). X_s indicates the experimentally detected position (open squares) of the
 422 swelling front with respect to its initial position X_{s0} . ΔX represents the distances of
 423 the erosion, diffusion and swelling fronts from their original position at $t=0$.
 424 Vertical bars indicate standard deviations ($n=3$).

425 The fact that D_m ($(6.1 \pm 0.32) \cdot 10^{-9} \text{ m}^2/\text{s}$) is bigger than acetaminophen diffusivity
 426 D in water ($7.8 \cdot 10^{-10} \text{ m}^2/\text{s}$) simply implies that the gel layer is pervaded by channels
 427 in which drug transport occurs not only by diffusion but also by convection (water
 428 convective motion inside channels). The high B ($(555822 \pm 30360) \text{ s/m}$) and the
 429 small b ($(1.57 \pm 0.2) \cdot 10^{-4} \text{ s}^{-1}$) values witness the presence of a thick gel (high B)
 430 whose erosion is very slow (low b). In addition, the values of the model fitting
 431 parameters allow to predict that the position of the diffusion front (dashed line in
 432 Figure 3B – eq.(9)) is always set back from the experimentally detected position of
 433 the swelling front (squares), as it is expected.

434 Model best fitting has also been performed simultaneously on release data and on
 435 erosion front position of matrices containing different amount of enzymatic

436 complex. In Figure 4 results of best fitting model (eq.(5) - solid lines) to release
 437 data (symbols) for all the considered formulations are presented.

438



439

440 Figure 4. Model best fitting (solid lines – eq.(5)) to experimental release data (M_d ,
 441 symbols) of partially coated matrices having different cellulase content (CM_0 ,
 442 $CM_{0.5}$, CM_1 , CM_5 , CM_{10}). Vertical bars indicate standard deviations ($n=3$).

443

444 An excellent agreement has been found between experimental and model best
 445 fitting data. This qualitative judgement is statistically supported by the score of the
 446 F -test reported in Table 3. In addition, model reliability is proved by the physical
 447 soundness of the fitting parameters values. Indeed, it can be seen that k_d is almost
 448 constant with cellulase content up to 1%, being always lower than that determined
 449 by IDR, regardless of the paddle rotation speed. Only when cellulase content is
 450 greater or equal to 5%, k_d approaches the intrinsic dissolution rate constant
 451 calculated for the lowest rotation speed considered (see Table 2).

452 Table 3. Model fitting parameters of experimental release data from partially coated matrices with different cellulase content (CM_0 ,
 453 $CM_{0.5}$, CM_1 , CM_5 , CM_{10}) and score of the statistic F-test for the simultaneous best fitting according to eq.(5) and eq.(9).

454


Matrix code	CM_0	$CM_{0.5}$	CM_1	CM_5	CM_{10}
$F(3,19,0.95)$	< 9660	< 4328	< 21989	< 10266	< 2085
k_d (m/s)	$(4.8 \pm 0.2) \cdot 10^{-6}$	$(4.7 \pm 0.2) \cdot 10^{-6}$	$(4.3 \pm 0.3) \cdot 10^{-6}$	$(5.3 \pm 0.2) \cdot 10^{-6}$	$(5.9 \pm 1.5) \cdot 10^{-6}$
D_m (m^2/s)	$(0.6 \pm 0.32) \cdot 10^{-8}$	$(1.0 \pm 0.05) \cdot 10^{-8}$	$(1.4 \pm 0.21) \cdot 10^{-8}$	$(2.6 \pm 0.20) \cdot 10^{-8}$	> 10^{-7}
B (s/m)	555822 ± 30360	285834 ± 14460	131820 ± 14340	75296 ± 8460	< 2000
b ($1/s$)	$(1.6 \pm 0.2) \cdot 10^{-4}$	$(2.8 \pm 0.1) \cdot 10^{-4}$	$(6.2 \pm 1.2) \cdot 10^{-4}$	$(4.3 \pm 0.6) \cdot 10^{-4}$	> 10^{-3}

455

456 This trend appears justifiable, as in matrices with a high cellulase content, the
457 integrity and uniformity of the gel could be diminished more efficiently.
458 Consequently, this makes the impact of water convection on drug transport no
459 longer negligible. Similarly, considering that the model accounts for the
460 contribution of drug transport by convection, an increase in the diffusion
461 coefficient (D_m) along with the cellulase content suggests an enhanced influence
462 of convection on drug transport within the gel layer.

463 Finally, the reduction of B and the increase of b with cellulase content point out
464 the formation of a progressively thinner gel layer, that evolves more quickly over
465 time (see eq.(3) and eq.(8)).

466 The outcomes of model fitting to experimental data can also be depicted by the
467 graph of time evolution of the ratio between drug release resistance due to drug
468 dissolution ($R_d = 1/k_d$) and the total resistance, *i.e.* the sum of R_d and R (resistance
469 due to the formation of the gel layer – eq.(8)) (Figure 5). In all the systems, in the
470 very early stage of drug release ($t \approx 0$ min), the ratio $R_d/(R_d+R)$ is ≈ 1 , meaning
471 that the resistance due to the gel layer is almost negligible compared to that due
472 to drug dissolution. As the gel layer thickness - and the associated R - increases,
473 the contribution of R_d to the total resistance progressively diminishes ($0 < t < 120$
474 min, approximately). This reduction settles at varying values depending on the
475 cellulase content. The lowest plateau value of ($R_d/(R_d + R)$) is observed for CM0
476 (0.28), and it progressively increases with cellulase concentration to the point that
477 at the highest cellulase concentration, it is maintained close to 1 throughout the
478 whole test period. This trend well correlates with alterations in gel characteristics
479 resulting from cellulase activity, which indeed leads to the formation of a
480 progressively thinner and more permeable swollen layer.



481


482 Figure 5. Temporal evolution of the drug dissolution resistance ($R_d = 1/k_d$) with
 483 respect to the total resistance (given by R_d and the resistance R exerted by the gel
 484 layer, eq.(8)) in partially-coated matrices having different cellulase content (CM_0 ,
 485 $CM_{0.5}$, CM_1 , CM_5 , CM_{10}).

486

487 3.3. Uncoated matrices

488 Release of drugs from partially coated matrices is, in principle, relatively simpler
 489 to describe than from uncoated. In the latter case, drug liberation takes place over
 490 the three-dimensional space and the existing fronts are not simple plane surfaces
 491 of constant area but consist of complex shape changing over time. Nevertheless,
 492 the proposed model proved able to fit the experimental data also in the case of
 493 uncoated tablets, as depicted in Figure 6 and supported by the outcome of the F-
 494 test reported in Table 4.

495



496

497 Figure 6. Model best fitting (solid lines – eq.(5)) to experimental release data (M_d ,
498 symbols) of uncoated matrices having different cellulase content (UM_0 , $UM_{0.5}$, UM_1 ,
499 UM_5 , UM_{10}). Vertical bars indicate data standard deviation (n=3).

500 Table 4. Model fitting parameters of experimental release data from uncoated matrices with different cellulase content (UM_0 ,
 501 $UM_{0.5}$, UM_1 , UM_5 , UM_{10}) and score of the statistic F-test for the best fitting according to eq.(5).


502

Matrix code	UM_0	$UM_{0.5}$	UM_1	UM_5	UM_{10}
<i>F-test score</i>	$F(2,29,0.95) < 12700$	$F(2,16,0.95) < 13259$	$F(2,13,0.95) < 10340$	$F(2,8,0.95) < 9078$	$F(2,5,0.95) < 2826$
k_d (m/s)	$(4.4 \pm 0.1) \cdot 10^{-6}$	$(4.3 \pm 0.2) \cdot 10^{-6}$	$(3.8 \pm 0.3) \cdot 10^{-6}$	$(4.7 \pm 0.3) \cdot 10^{-6}$	$(4.3 \pm 0.7) \cdot 10^{-6}$
B (s/m)	2746066 ± 314340	1019693 ± 14460	1082343 ± 334920	218532 ± 115680	99330 ± 21240
B (1/s)	$(3.1 \pm 0.5) \cdot 10^{-5}$	$(6.8 \pm 1.0) \cdot 10^{-5}$	$(3.8 \pm 1.3) \cdot 10^{-4}$	$(3.6 \pm 0.6) \cdot 10^{-4}$	$(4.3 \pm 3.7) \cdot 10^{-4}$

503

504 The values of k_d calculated for the uncoated matrices at different cellulase content
 505 are rather similar and always lower than those obtained from IDR experiment at
 506 any rotational speed (see Table 2). Moreover, k_d values are quite close to those
 507 calculated for partially coated tablets (see Table 3), thus substantiating that the
 508 dissolution process at the solid-liquid interface is not affected by the different
 509 shape of the moving fronts in the two matrix configurations. Temporal evolution
 510 of the drug dissolution resistance ($R_d = 1/k_d$) with respect to the total resistance is
 511 shown in Figure 7.

512



513

514 Figure 7. Temporal evolution of the drug dissolution resistance ($R_d = 1/k_d$) with
 515 respect to the total resistance (given by R_d and the resistance R exerted by the gel
 516 layer, eq.(8)) in uncoated matrices having different cellulase content (UM_0 , $UM_{0.5}$,
 517 UM_1 , UM_5 , UM_{10} , coated tablets). Dashed lines represent data of partially-coated
 518 matrices having same composition (CM_0 , $CM_{0.5}$, CM_1 , CM_5 , CM_{10}).

519

520 Despite an overall similar trend, the uncoated matrices present different kinetics
 521 of gel formation and final pseudo-stationary condition as compared to partially

522 coated ones (dashed line in Figure 7). In fact, whatever the cellulase concentration,
523 the value of $R_d/(R_d + R)$ at the end of the test is always smaller in the case of the
524 uncoated units, which would suggest that the resistance caused by the gel barrier
525 more remarkably affects the release process in the case of uncoated matrices

526

527 **4. CONCLUSIONS**

528 A mathematical model previously developed was able to describe drug release
529 from HPMC-based HMs containing drugs with different solubility. The applied
530 semi-empirical model took into account the contribution to drug diffusion
531 resistance associated with the dissolution phenomenon and the presence of a gel
532 layer. In the present work, an evaluation of the suitability of such a model to
533 describe drug release from HPMC matrices containing a cellulolytic enzymatic
534 complex (cellulase) was carried out. Preliminary Acetaminophen IDR data
535 obtained at different paddle rotational speed were fitted according to the Levich
536 theory, highlighting good surface wettability properties. The model here reported
537 accurately describes drug release from matrices lacking (free of) and containing
538 increasing amounts of the enzyme.

539 Two new equations were also introduced that allowed to estimate the position of
540 the erosion and diffusion fronts over time. The experimental data for the position
541 of the erosion front and those predicted by the model were in good agreement,
542 while the diffusion front was found to be consistently positioned between the
543 swelling and erosion fronts.

544 The output parameters related to gel properties are characterized by physical
545 soundness, according to the expected impact of cellulase. This can be seen by the
546 change in the relative contributions to total resistance associated with both the
547 drug dissolution process and the thickness and permeability of the swollen layer.
548 The enzyme has been shown to progressively reduce gel resistance to drug
549 diffusion over time in a concentration-dependent manner. In fact, for the highest
550 percentage of cellulolytic product, the resulting very thin and permeable gel layer
551 does not contribute at all to the total resistance throughout the whole release test.

552 The suitability of the proposed equations was also confirmed on uncoated
553 matrices, where the overall picture is complicated by the reduction of the swelling
554 front interface over time.

555 The dissolution and gel layer contributions to total resistance to drug diffusion as
556 well as fronts positions time course are important aspects to be taken into account
557 for the definition of the release mechanism from HMs. The model successfully
558 described the changes of such phenomena in matrix systems containing an
559 enzyme acting as erosion enhancer. The same equations could be exploited to
560 deepen the possible impact of other “active” excipients on the overall HMs release
561 performance.

562

563 **References**

- 564 Abrami, M., Grassi, L., Di Vittorio, R., Hasa, D., Perissutti, B., Voinovich, D., Grassi,
565 G., Colombo, I., Grassi, M., 2020. Dissolution of an ensemble of differently
566 shaped poly-dispersed drug particles undergoing solubility reduction:
567 mathematical modelling. *ADMET DMPK* 8, 297–313.
568 <https://doi.org/10.5599/admet.841>
- 569 Adrover, A., Varani, G., Paolicelli, P., Petralito, S., Di Muzio, L., Casadei, M.A., Tho,
570 I., 2018. Experimental and Modeling Study of Drug Release from HPMC-
571 Based Erodible Oral Thin Films. *Pharmaceutics* 10, 222.
572 <https://doi.org/10.3390/PHARMACEUTICS10040222>
- 573 Caccavo, D., Lamberti, G., Barba, A.A., Abrahmsén-Alami, S., Viridén, A., Larsson,
574 A., 2017. Effects of HPMC substituent pattern on water up-take, polymer and
575 drug release: An experimental and modelling study. *Int J Pharm* 528, 705–
576 713. <https://doi.org/10.1016/j.ijpharm.2017.06.064>
- 577 Caceres, M., Petit, E., Deratani, A., 2020. Partial depolymerization of
578 hydroxypropylmethyl cellulose for production of low molar mass polymer
579 chains. *Carbohydr Polym* 229, 115461.
580 <https://doi.org/10.1016/j.carbpol.2019.115461>
- 581 Cappello, B., Del Nobile, M.A., La Rotonda, M.I., Mensitieri, G., Miro, A., Nicolais,
582 L., 1994. Water soluble drug delivery systems based on a non-biological
583 bioadhesive polymeric system. *Farmaco* 49, 809–818.

- 584 Cerea, M., Foppoli, A., Palugan, L., Melocchi, A., Zema, L., Maroni, A., Gazzaniga,
585 A., 2020a. Non-uniform drug distribution matrix system (NUDDMat) for zero-
586 order release of drugs with different solubility. *Int J Pharm* 581, 119217.
587 <https://doi.org/10.1016/j.ijpharm.2020.119217>
- 588 Cerea, M., Maroni, A., Palugan, L., Bellini, M., Foppoli, A., Melocchi, A., Zema, L.,
589 Gazzaniga, A., 2018. Novel hydrophilic matrix system with non-uniform drug
590 distribution for zero-order release kinetics. *Journal of Controlled Release* 287,
591 247–256. <https://doi.org/10.1016/j.jconrel.2018.08.027>
- 592 Cerea, M., Maroni, A., Palugan, L., Moutaharrik, S., Melocchi, A., Zema, L., Foppoli,
593 A., Gazzaniga, A., 2020b. Oral hydrophilic matrices having non uniform drug
594 distribution for zero-order release: A literature review. *Journal of Controlled*
595 *Release* 325, 72–83. <https://doi.org/10.1016/j.jconrel.2020.06.033>
- 596 Chirico, S., Dalmoro, A., Lamberti, G., Russo, G., Titomanlio, G., 2007. Analysis and
597 modeling of swelling and erosion behavior for pure HPMC tablet. *Journal of*
598 *Controlled Release* 122, 181–188.
599 <https://doi.org/10.1016/j.jconrel.2007.07.001>
- 600 Colombo, P., 1993. Swelling-controlled release in hydrogel matrices for oral route.
601 *Adv Drug Deliv Rev* 11, 37–57. [https://doi.org/10.1016/0169-](https://doi.org/10.1016/0169-409X(93)90026-Z)
602 [409X\(93\)90026-Z](https://doi.org/10.1016/0169-409X(93)90026-Z)
- 603 Colombo, P., Bettini, R., Massimo, G., Catellani, P.L., Santi, P., Peppas, N.A., 1995.
604 Drug diffusion front movement is important in drug release control from
605 swellable matrix tablets. *J Pharm Sci* 84, 991–997.
- 606 Colombo, P., Bettini, R., Peppas, N.A., 1999. Observation of swelling process and
607 diffusion front position during swelling in hydroxypropyl methyl cellulose
608 (HPMC) matrices containing a soluble drug. *Journal of Controlled Release* 61,
609 83–91.
- 610 Colombo, P., Bettini, R., Santi, P., Peppas, N.A., 2000. Swellable matrices for
611 controlled drug delivery: gel-layer behaviour, mechanisms and optimal
612 performance. *Pharm Sci Technol Today* 3, 198–204.
613 [https://doi.org/10.1016/S1461-5347\(00\)00269-8](https://doi.org/10.1016/S1461-5347(00)00269-8)
- 614 Colombo, P., Gazzaniga, A., Caramella, C., Conte, U., La Manna, A., 1987. In vitro
615 programmable zero-order release drug delivery system. *Acta Pharmaceutica*
616 *Technologica* 33, 15–20.

- 617 Conte, U., Maggi, L., Colombo, P., Manna, A. La, 1993. Multi-layered hydrophilic
618 matrices as constant release devices (Geomatrix™ Systems). *Journal of*
619 *Controlled Release* 26, 39–47.
- 620 Deering, R.P., Kommareddy, S., Ulmer, J.B., Brito, L.A., Geall, A.J., 2008.
621 Modulation of drug release from hydrophilic matrices. *Pharmaceutical*
622 *Technology Europe* 20, 885–899.
623 <https://doi.org/10.1517/17425247.2014.901308>
- 624 Demidovic, B.P., 1975. *Esercizi e problemi di analisi matematica*, Sixth. ed. Editori
625 Riuniti, Rome.
- 626 ECHA, 2012. Paracetamol Registration Dossier [WWW Document]. URL
627 [https://echa.europa.eu/it/registration-dossier/-/registered-](https://echa.europa.eu/it/registration-dossier/-/registered-dossier/12532/4/5)
628 [dossier/12532/4/5](https://echa.europa.eu/it/registration-dossier/-/registered-dossier/12532/4/5) (accessed 11.7.23).
- 629 Ferrero, C., Massuelle, D., Doelker, E., 2010. Towards elucidation of the drug
630 release mechanism from compressed hydrophilic matrices made of cellulose
631 ethers. II. Evaluation of a possible swelling-controlled drug release mechanism
632 using dimensionless analysis. *Journal of Controlled Release* 141, 223–233.
633 <https://doi.org/10.1016/j.jconrel.2009.09.011>
- 634 Flynn, G.L., Yalkowsky, S.H., Roseman, T.J., 1974. Mass Transport Phenomena
635 and Models: Theoretical Concepts. *J Pharm Sci* 63, 479–510.
- 636 Foppoli, A., Maroni, A., Palugan, L., Zema, L., Moutaharrik, S., Melocchi, A., Cerea,
637 M., Gazzaniga, A., 2020. Erodible coatings based on HPMC and cellulase for
638 oral time-controlled release of drugs. *Int J Pharm* 585, 119425.
639 <https://doi.org/10.1016/j.ijpharm.2020.119425>
- 640 Ford, J.L., Rubinstein, M.H., McCaul, F., Hogan, J.E., Penny Edgar, -and J, 1987.
641 Importance of drug type, tablet shape and added diluents on drug release
642 kinetics from hydroxypropylmethylcellulose matrix tablets. *Int J Pharm* 40,
643 223–234.
- 644 Gander, B., Gurny, R., Doelker, E., Peppas, N.A., 1988. Crosslinked Poly(Alkylene
645 Oxides) for the preparation of controlled release micromatrices. *Journal of*
646 *Controlled Release* 5, 271–283.
- 647 Gazzaniga, A., Moutaharrik, S., Filippin, I., Foppoli, A., Palugan, L., Maroni, A.,
648 Cerea, M., 2022. Time-Based Formulation Strategies for Colon Drug Delivery.
649 *Pharmaceutics* 14, 2762. <https://doi.org/10.3390/pharmaceutics14122762>

- 650 Gazzaniga, A., Sangalli, M.E., Conte, U., Caramella, C., Colombo, P., La Manna, A.,
651 1993. On the release mechanism from coated swellable minimatrices. *Int J*
652 *Pharm* 91, 167–171. [https://doi.org/10.1016/0378-5173\(93\)90336-E](https://doi.org/10.1016/0378-5173(93)90336-E)
- 653 Ghori, M.U., Conway, B.R., 2015. Hydrophilic Matrices for Oral Control Drug
654 Delivery. *Am J Pharmacol Sci* 3, 103–109.
655 <https://doi.org/https://doi.org/10.12691/ajps-3-5-1>
- 656 Grassi, M., Grassi, G., Lapasin, R., Colombo, I., 2006. Drug Dissolution and
657 Partitioning, in: *Understanding Drug Release and Absorption Mechanisms. A*
658 *Physical and Mathematical Approach*. CRC Press, Boca Raton, FL, pp. 249–
659 332. <https://doi.org/10.1201/9781420004656>
- 660 Grassi, M., Zema, L., Sangalli, M.E., Maroni, A., Giordano, F., Gazzaniga, A., 2004.
661 Modeling of drug release from partially coated matrices made of a high
662 viscosity HPMC. *Int J Pharm* 276, 107–114.
663 <https://doi.org/10.1016/j.ijpharm.2004.02.016>
- 664 Guiastrennec, B., Söderlind, E., Richardson, S., Peric, A., Bergstrand, M., 2017. In
665 *Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix*
666 *Tablet Erosion Under Fasting and Postprandial Status*. *Pharm Res* 34, 847–
667 859. <https://doi.org/10.1007/s11095-017-2113-7>
- 668 Harland, R.S., Gazzaniga, A., Sangalli, M.E., Colombo, P., Peppas, N.A., 1988.
669 Drug/Polymer Matrix Swelling and Dissolution. *Pharmaceutical Research: An*
670 *Official Journal of the American Association of Pharmaceutical Scientists* 5,
671 488–494. <https://doi.org/10.1023/A:1015913207052>
- 672 Iqbal, M.J., Malik, Q.M., 2005. Partial molar volume of paracetamol in water, 0.1M
673 HCl and 0.154M NaCl at T=(298.15, 303.15, 308.15 and 310.65)K and at
674 101.325kPa. *J Chem Thermodyn* 37, 1347–1350.
675 <https://doi.org/10.1016/j.jct.2005.03.008>
- 676 Jamzad, S., Tutunji, L., Fassihi, R., 2005. Analysis of macromolecular changes and
677 drug release from hydrophilic matrix systems. *Int J Pharm* 292, 75–85.
678 <https://doi.org/10.1016/j.ijpharm.2004.11.011>
- 679 Jantzen, G.M., Robinson, J.R., 2002. Sustained- and Controlled-Release Drug
680 Delivery Systems, in: Banker, G., Rhodes, C. (Eds.), *Modern Pharmaceutics*.
681 Marcel Dekker, Basel, pp. 503–530.

- 682 Khoury, N., Mauger, J.W., Howard, S., 1988. Dissolution Rate Studies from a
683 Stationary Disk/Rotating Fluid System. *Pharm Res* 5, 495–500.
- 684 Kim, C. ju, 1995. Compressed Donut-Shaped Tablets with Zero-Order Release
685 Kinetics. *Pharmaceutical Research: An Official Journal of the American*
686 *Association of Pharmaceutical Scientists* 12, 1045–1048.
687 <https://doi.org/10.1023/A:1016218716951>
- 688 Laracuenta, M.L., Yu, M.H., McHugh, K.J., 2020. Zero-order drug delivery: State of
689 the art and future prospects. *Journal of Controlled Release* 327, 834–856.
690 <https://doi.org/10.1016/j.jconrel.2020.09.020>
- 691 Levich, V.G., 1962. *Physicochemical Hydrodynamics*. Prentice-Hall, Englewood,
692 NJ.
- 693 Lombardi, C., Zema, L., Sangalli, M.E., Maroni, A., Giordano, F., Gazzaniga, A.,
694 1998. Influence of drug/polymer ratio on the release from heterogeneous high
695 viscosity HPMC matrices. ., in: *World Meeting APGI/APV*. pp. 335–336.
- 696 Loreti, G., Maroni, A., Dorly, M., Curto, D., Melocchi, A., Gazzaniga, A., Zema, L.,
697 2013. Evaluation of hot-melt extrusion technique in the preparation of HPC
698 matrices for prolonged release. <https://doi.org/10.1016/j.ejps.2013.10.014>
- 699 Mašková, E., Kubová, K., Raimi-Abraham, B.T., Vllasaliu, D., Vohlídalová, E.,
700 Turánek, J., Mašek, J., 2020. Hypromellose-A traditional pharmaceutical
701 excipient with modern applications in oral and oromucosal drug delivery.
702 *Journal of Controlled Release* 324, 695–727.
703 <https://doi.org/10.1016/j.jconrel.2020.05.045>
- 704 Moodley, K., Pillay, V., Choonara, Y.E., du Toit, L.C., Ndesendo, V.M.K., Kumar, P.,
705 Cooppan, S., Bawa, P., 2011. Oral Drug Delivery Systems Comprising Altered
706 Geometric Configurations for Controlled Drug Delivery. *Int J Mol Sci* 13, 18–
707 43. <https://doi.org/10.3390/ijms13010018>
- 708 Palugan, L., Filippin, I., Cirilli, M., Moutaharrik, S., Zema, L., Cerea, M., Maroni, A.,
709 Foppoli, A., Gazzaniga, A., 2021. Cellulase as an “active” excipient in
710 prolonged-release HPMC matrices: A novel strategy towards zero-order
711 release kinetics. *Int J Pharm* 607, 121005.
712 <https://doi.org/10.1016/j.ijpharm.2021.121005>
- 713 Peppas, N.A., Narasimhan, B., 2014. Mathematical models in drug delivery: How
714 modeling has shaped the way we design new drug delivery systems. *Journal*

- 715 of Controlled Release 190, 75–81.
716 <https://doi.org/10.1016/j.jconrel.2014.06.041>
- 717 Ranga Rao, K V, Padmalatha Devi, K., Buri, P., Ranga Rao, KV, 1988. Cellulose
718 Matrices for Zero-Order Release of Soluble Drugs. *Drug Dev Ind Pharm* 14,
719 2299–2320. <https://doi.org/10.3109/03639048809152017>
- 720 Rogers T L, 2009. Hypromellose, in: Rowe, R.C., Sheskey, P.J., Quinn, M.E. (Eds.),
721 Handbook of Pharmaceutical Excipients. Pharmaceutical Press, London, pp.
722 326–329.
- 723 Saeidipour, F., Mansourpour, Z., Mortazavian, E., Rafiee-Tehrani, N., Rafiee-
724 Tehrani, M., 2017. New comprehensive mathematical model for HPMC-MCC
725 based matrices to design oral controlled release systems. *European Journal of*
726 *Pharmaceutics and Biopharmaceutics* 121, 61–72.
727 <https://doi.org/10.1016/j.ejpb.2017.09.007>
- 728 Sai Cheong Wan, L., Wan Sia Heng, P., Fun Wong, L., 1995. Matrix swelling: A
729 simple model describing extent of swelling of HPMC matrices. *Int J Pharm*
730 116, 159–168. [https://doi.org/10.1016/0378-5173\(94\)00285-D](https://doi.org/10.1016/0378-5173(94)00285-D)
- 731 Salsa, T., Veiga, F., Pina, M.E., 2008. Oral Controlled-Release Dosage Forms. I.
732 Cellulose Ether Polymers in Hydrophilic Matrices. *Drug Dev Ind Pharm* 23,
733 929–938. <https://doi.org/10.3109/03639049709148697>
- 734 Sangalli, M.E., Giunchedi, P., Maggi, L., Conte, U., Gazzaniga, A., 1994. Inert
735 monolithic device with a central hole for constant drug release. *European*
736 *Journal of Pharmaceutics and Biopharmaceutics* 40, 370–373.
- 737 Siepmann, J., Peppas, N.A., 2012. Modeling of drug release from delivery systems
738 based on hydroxypropyl methylcellulose (HPMC). *Adv Drug Deliv Rev* 64,
739 163–174. <https://doi.org/10.1016/j.addr.2012.09.028>
- 740 Siepmann, J., Peppas, N.A., 2001. Modeling of drug release from delivery systems
741 based on hydroxypropyl methylcellulose (HPMC). *Adv Drug Deliv Rev* 48,
742 139–157. [https://doi.org/10.1016/S0169-409X\(01\)00112-0](https://doi.org/10.1016/S0169-409X(01)00112-0)
- 743 Timmins, P., Desai, D., Chen, W., Wray, P., Brown, J., Hanley, S., 2016. Advances
744 in mechanistic understanding of release rate control mechanisms of extended-
745 release hydrophilic matrix tablets. *Ther Deliv* 7, 553–572.
746 <https://doi.org/10.4155/tde-2016-0026>

- 747 Tiwari, S.B., Rajabi-Siahboomi, A.R., 2008. Extended-Release Oral Drug Delivery
748 Technologies: Monolithic Matrix Systems, in: Jain, K.K. (Ed.), Drug Delivery
749 Systems. Humana Press, Totowa, NJ, pp. 217–244.
- 750 Tiwari, S.P., DiNunzio, J., Rajabi-Siahboomi, A., 2011. Drug–Polymer Matrices for
751 Extended Release, in: Wilson, C.G., Crowley, P.J. (Eds.), Controlled Release in
752 Oral Drug Delivery. Springer, New York, pp. 131–159.
- 753 Vázquez, M.J., Pérez-Marcos, B., Gómez-Amoza, J., Martínez -Pacheco, R., Souto,
754 C., Concheiro, A., 1992. Influence of technological variables on release of
755 drugs from hydrophilic matrices. Drug Dev Ind Pharm 18, 1355–1375.
756 <https://doi.org/10.3109/03639049209046332>
- 757 Wang, S., Liu, R., Fu, Y., Kao, W.J., 2020. Release mechanisms and applications of
758 drug delivery systems for extended-release. Expert Opin Drug Deliv 17, 1289–
759 1304. <https://doi.org/10.1080/17425247.2020.1788541>
- 760 Wen, X., Nokhodchi, A., Rajabi-Siahboomi, A., 2010. Oral extended release
761 hydrophilic matrices: formulation and design, in: Wen, H., Park, K. (Eds.), Oral
762 Controlled Release Formulation Design and Drug Delivery : Theory to
763 Practice. Wiley, New Jersey, pp. 89–100.
- 764 Zhang, F., McGinity, J.W., 1999. Properties of Sustained-Release Tablets Prepared
765 by Hot-Melt Extrusion. Pharm Dev Technol 4, 241–250.
766 <https://doi.org/10.1081/PDT-100101358>
767